Close

Form 6-K GLAXOSMITHKLINE PLC For: Apr 18

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 4/19/2024

1. NFLX
2. TSM
3. ISRG
4. SPY
5. INFY
6. SNV
7. TSLA
8. SMCI
9. SLB
10. PPG


April 18, 2016 12:45 PM EDT

FORM 6-K
 
 
SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549
 
 
Report of Foreign Issuer
 
 
Pursuant to Rule 13a-16 or 15d-16 of

the Securities Exchange Act of 1934
 
 
 
For period ending April 2016
 
GlaxoSmithKline plc
(Name of registrant)


 
 
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)


 
 
Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F


 
 
Form 20-F x     Form 40-F

 
--

 
Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.


 
 
Yes      No x
--
 
 
 
 
 
                                                                                                                            GlaxoSmithKline plc
 
Notification of Transactions of Directors, Persons Discharging Managerial Responsibilities or Connected Persons
 
In accordance with DTR 3.1.4 R(1)(a) and (c) GlaxoSmithKline plc ('GSK') was advised on 18 April 2016 that the following acquisitions of GSK Ordinary shares took place, at a price of 1503.58 pence per Ordinary share, following the re-investment of the dividend paid to shareholders on 14 April 2016:
 
 
 Director/PDMR
 
Number of Ordinary shares
 
 
 Sir Andrew Witty
 
15,070
 
 Mrs V A Whyte
 
100
 
 
 
 Connected Person
 
Number of Ordinary shares
 
 Lady C Witty
 (Connected Person of Sir Andrew Witty)
 
4,705
 
 Mr I W Whyte (Connected Person of Mrs V A Whyte)
 
835
 
 Mrs D Connor (Connected Person of Mr R G Connor)
 
534
 
 
V A Whyte
Company Secretary
 
18 April 2016


 
 
 
 
 

 
SIGNATURES
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.



 
 
GlaxoSmithKline plc
(Registrant)


Date: April 18, 2016 
 
 
By: VICTORIA WHYTE
----------------------
 
 
Victoria Whyte
Authorised Signatory for and on
behalf of GlaxoSmithKline plc


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

SEC Filings